Microsoft ( MSFT -1.55%) posted results for the fiscal first quarter of 2027 (the three months ending Sept. 30, 2026) on ...
Aggressive reinvestment is expanding Vertiv's manufacturing scale while the company maintains high profitability, a balance ...
AbbVie also raised its full-year outlook, although the increase was relatively small. Management guided to adjusted EPS in ...
An investment in Anthropic clearly offers investors access to tremendous growth, but risk is high -- so while certain ...
Anduril may be private, but these three publicly traded defense giants could give investors a way to profit from America's ...
By most measures, Rocket Lab (RKLB-7.39%) shares should be well higher. As of July, its backlog stood at $2.36 billion, or ...
Owning its network infrastructure lets Bandwidth monetize AI-driven call volume without absorbing the computing costs rivals ...
Michael Burry hasn't backed off his bet against Palantir Technologies (PLTR-6.27%). When the investor of The Big Short fame ...
A decade of aggressive buybacks has shrunk the share count by 37%, amplifying per-share earnings even as revenue growth ...
In its 2027 Long-Term Capital Market Assumptions report published in October 2026, J.P. Morgan projects that Bitcoin ( BTC +0 ...
Lilly is the maker of tirzepatide, a drug sold under the name Mounjaro for type 2 diabetes and as Zepbound for weight loss.
The e-commerce company has beaten its own forecast all year. Is a cheaper stock enough to buy ahead of the next one?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results